Amphotericin B Bone Cement via Micellar Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone cements lack effective antimycotic agents that can be released in aqueous environments, such as body fluids, to combat fungal infections in orthopedic implants, particularly due to the poor water solubility and protein binding of common antimycotic agents like amphotericin B.
Innovation Solution
A polymethylmethacrylate bone cement is developed with amphotericin B encapsulated by a mixture of 1-methylamino-1-deoxy sugar alcohol and fatty acids, which improves the water solubility of the antimycotic agent without using solvents, allowing for homogeneous distribution and release in aqueous media.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If common antimycotic agents like amphotericin B are admixed to polymethylmethacrylate bone cement, then the bone cement gains antimycotic properties, but the poor water solubility and high protein binding of these agents prevent effective release in aqueous body fluids
Solution Approach 1:
The patent uses amphiphilic compounds as intermediary substances that form mixed micelles with amphotericin B. These micelles act as carriers that solubilize the hydrophobic antimycotic agent in the aqueous environment of body fluids, enabling effective release while maintaining antimycotic activity. The amphiphilic nature of these compounds allows them to interact with both the hydrophobic amphotericin B and the hydrophilic body fluids.
Solution Approach 2:
The patent changes the physical-chemical parameters of the antimycotic agent system by forming micellar structures. This transforms the poor water-soluble amphotericin B into a water-soluble micellar complex, fundamentally altering its solubility characteristics without changing the active pharmaceutical ingredient itself. The micellization process changes the aggregation state and surface properties of the antimycotic agent.
2Ease of manufacture
If antimycotic agents with poor water solubility are used, then the bone cement can be manufactured with standard materials, but dissolution and release of the agent from the hydrophobic polymethylmethacrylate cement is difficult and ineffective
Solution Approach 1:
The patent creates a composite system combining amphotericin B with amphiphilic compounds that have both hydrophobic and hydrophilic characteristics. This composite micellar structure allows the hydrophobic antimycotic agent to be effectively delivered in a hydrophilic environment, solving the solubility problem while maintaining manufacturing simplicity. The composite nature of the micelles provides both stability in the cement matrix and solubility in body fluids.
3Ease of manufacture
If amphotericin B is encapsulated by 1-methylamino-1-deoxy sugar alcohol and fatty acid mixture, then water solubility is improved without using solvents, but the production process becomes more complex
Solution Approach 1:
The patent divides the solubilization task between two distinct components: 1-methylamino-1-deoxy sugar alcohol and fatty acid. This segmentation allows each component to contribute its specific properties (hydrophilicity from the sugar alcohol, hydrophobic interaction from the fatty acid) to form the mixed micelle structure. The segmented approach simplifies the overall process compared to using complex single-molecule surfactants.
Solution Approach 2:
The patent performs preliminary encapsulation of amphotericin B in the amphiphilic compound mixture before incorporating it into the bone cement. This preliminary action of forming the micellar complex in advance ensures that the solubility enhancement is already achieved before the cement is applied, simplifying the overall manufacturing process by separating the solubilization step from the cement formulation step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cement effectively releases antimycotically active amounts of amphotericin B, providing broad-spectrum efficacy against pathogenic fungi, enhancing the treatment and prevention of mycoses in orthopedic implant infections.
Implementation Method 1
the amphotericin B is encapsulated, at least in part, by a mixture of at least one 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid... which improves the water solubility of the antimycotic agent without using solvents
Implementation Method 2
It binds to the steroid, ergosterine, that is typical of fungi and is an ingredient of the fungal cell membrane. The fungicidal effect of amphotericin B has been related to an increase in the permeability of cell membranes for potassium ions
Implementation Method 3
the antimycotic agent is released from the polymerised bone cement in the presence of water or aqueous media, such as body fluids
Data Source
AI summary
The invention describes a bone cement with antimycotic efficacy based on organic polymers, such as polymethylmethacrylate. The bone cement comprises an antimycotic agent, in particular amphotericin B, that is released from the polymerized bone cement in the presence of water or aqueous media, such as body fluids. According to one alternative, the antimycotic agent is present in particulate form and is encapsulated, at least in part, by a mixture of at least one 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid. In addition, a method for the production of a mixture comprising an antimycotic agent, such as amphotericin B particles, and 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid is proposed. Preferably, the antimycotic agent is encapsulated, at least partially, by 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid.